Immune Modulating Regimen for Malignancy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as chemotherapy and radiation therapy, often fail due to immunosuppression associated with tumors, leading to ineffective elimination of malignant cells and metastasis, highlighting the need for improved immune modulation techniques to enhance therapeutic outcomes.
Innovation Solution
The use of a pharmaceutical composition that modulates the immune system by increasing the ratio of interleukin-15 (IL-15) to interleukin-6 (IL-6) activity, comprising a combination of histamine H2 receptor antagonists, adenosine 2A receptor inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), vitamin A, and vitamin D receptor ligands, to potentiate chemotherapy and radiation therapy and improve immune response against tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapeutic and radiation therapy regimes are used, then treatment is administered, but the therapies are not successful due to immunosuppression associated with the tumor
Solution Approach 1:
The patent converts the tumor's immunosuppressive effect from a harmful factor into a beneficial target for therapy. By administering compositions that specifically counteract immunosuppression (such as blocking TGF-beta, PD-L1, or IDO pathways), the treatment transforms the tumor's escape mechanism into a vulnerability that can be exploited to enhance immune-mediated tumor cell elimination and improve therapeutic success
Solution Approach 2:
The patent introduces intermediary substances (immune-modulating compositions containing cytokines like IL-2, IL-15, IL-18, or blocking agents against immunosuppressive pathways) that mediate between the conventional chemotherapy/radiation therapy and the immune system. These intermediaries restore immune competence without requiring changes to the primary cancer treatment protocols
2Productivity
If the immune system is not modulated, then current therapies are administered, but the ability to eliminate malignant cells is insufficient leading to metastasis
Solution Approach 1:
The patent applies preliminary action by administering immune-modulating compositions before or during conventional cancer therapy to pre-activate or restore immune surveillance capabilities. This preliminary immune enhancement ensures that the immune system is primed and competent to eliminate malignant cells and prevent metastatic spread before the tumor can establish secondary sites
Solution Approach 2:
The patent changes key immune system parameters (such as increasing cytokine levels IL-2, IL-15, IL-18, or blocking immunosuppressive signals) to shift the immune system from a suppressed state to an activated state, thereby enhancing the productivity of tumor cell elimination and improving reliability of metastasis prevention
Data Source
AI summary
The invention provides compositions, formulations, and methods for treatment of malignancies via activation of an inflammatory response in the subject. Such compositions, formulations, and methods for are preferably used in conjunction with other therapies for the treatment and/or management of malignancies, e.g., chemotherapy and/or radiation. The invention also provides methods of monitoring immune activation in subjects with malignancies.